Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 922-926, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-982152
ABSTRACT
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic tumor originated from hematopoietic stem cells. FLT3 is an important receptor tyrosine kinase in cell signal transduction pathway and one of the common mutated genes in AML. AML patients with FLT3-ITD mutation have a poor prognosis and tendency to relapse. Therefore, early identification of FLT3 gene mutation and selection of appropriate treatment are particularly important. Currently, the small moleculetargeted drugs have been new treatment methods for AML patients with FLT3-ITD mutation, but accompanied drug resistance need to be solved. This paper reviews the mechanism of FLT3 mutation, the clinical significance of FLT3 mutation in AML, FLT3 inhibitors and drug resistance mechanism.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Leukemia, Myeloid, Acute
/
Signal Transduction
/
Receptor Protein-Tyrosine Kinases
/
Protein Kinase Inhibitors
/
Fms-Like Tyrosine Kinase 3
/
Mutation
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS